Ponatinib: A Review of the History of Medicinal Chemistry behind Its Development

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Computational Chemistry

Background:

• First- and second-generation tyrosine kinase inhibitors (TKIs) are primary treatments for chronic myeloid leukemia (CML).
• These TKIs exhibit limited efficacy against specific ABL1 kinase domain mutations, notably the T315I mutation.
• Ponatinib (PNT), a third-generation TKI, was developed to overcome resistance, including the T315I mutation.

Purpose of the Study:

• To compile and chronologically organize research on the discovery and development of ponatinib.
• To elucidate the application of medicinal chemistry tools and computational methods in PNT's development.
• To provide a foundation for future optimization and analog development of PNT for CML and ALL treatment.

Main Methods:

• Review of existing literature on ponatinib's discovery and development.
• In silico calculations, including octanol/water partition coefficient (cLogP) using SwissAdme.
• Molecular docking to generate 2D maps of intermolecular interactions.

Main Results:

• Ponatinib demonstrates efficacy against the BCR-ABL1^T315I mutation, addressing limitations of earlier TKIs.
• Computational methods like cLogP and molecular docking were integral to understanding PNT's properties and interactions.
• The review consolidates historical data, offering a comprehensive overview of PNT's journey.

Conclusions:

• Ponatinib represents a significant advancement in CML and Philadelphia chromosome-positive ALL treatment, particularly for resistant mutations.
• The integration of medicinal chemistry and computational approaches was crucial for PNT's successful development.
• This consolidated review facilitates a deeper understanding and guides future research for improved TKI therapies.